Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vaginal cytology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Vaginal cytology. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-000158-36 Sponsor Protocol Number: OXYPEP202 Start Date*: 2016-03-18
    Sponsor Name:PEPTONIC medical AB
    Full Title: A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy
    Medical condition: Vaginal Atrophy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004872 10047782 Vulvovaginal atrophy LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004864-37 Sponsor Protocol Number: ASP-OP3-1 Start Date*: 2018-05-16
    Sponsor Name:Aspen Global Incorporated
    Full Title: A Multinational, Phase 3, Double-blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of Ovestin in the Treatment of Symptoms of Vulvar and Vaginal Atrophy in Postmenopausa...
    Medical condition: Vulvovaginal atrophy associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10047782 Vulvovaginal atrophy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-001791-36 Sponsor Protocol Number: 310781 Start Date*: 2008-01-24
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and 3 mg ZK 283197, 1 mg 17ß-estradiol and placebo onc...
    Medical condition: Vasomotor symptoms (hot flushes)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001629-24 Sponsor Protocol Number: VAG-1748 Start Date*: 2006-10-26
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 12 month, open-label, multi-center trial to investigate the endometrial safety of Vagifem Low Dose (10ug 17beta-estradiol vaginal tablet) in postmenopausal women with atrophic vaginitis symptoms....
    Medical condition: atrophic vaginitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003690 Atrophic vaginitis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) SE (Completed) DK (Completed) FI (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-000915-26 Sponsor Protocol Number: 000295 Start Date*: 2019-05-10
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A randomised, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resol...
    Medical condition: Deep infiltrating endometriosis, endometrioma and/or adenomyosis.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004872 10014787 Endometriosis of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003120-37 Sponsor Protocol Number: UFK 2008-002 Start Date*: 2009-05-15
    Sponsor Name:Medizinische Fakultät der Otto von Guericke Universität Magdeburg
    Full Title: EV(E)A Studie Estriol versus Estradiol - Eine prospektive, randomisierte Multizenterstudie zur Evaluation der Wirkung einer lokalen Therapie auf urogenitale Beschwerden, Zytologie und Mammographie...
    Medical condition: vaginal atrophy in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015504 Estriol LLT
    9.1 10015499 Estradiol LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002308-10 Sponsor Protocol Number: TOPIC-2 Start Date*: 2015-10-20
    Sponsor Name:
    Full Title: A randomized, single blinded trial to evaluate the efficacy of Imiquimod in women with residual/recurrent Cervical Intraepithelial Neoplasia (CIN) after previous treatment
    Medical condition: Residual or recurrent Cervical Intraepithelial Neoplasia (CIN)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004518-32 Sponsor Protocol Number: ITIC2-2.3 Start Date*: 2013-02-13
    Sponsor Name:Medizinische Universität Wien
    Full Title: ITIC2 Trial - Topical Imiquimod versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial
    Medical condition: In this randomized controlled, multi-center trial we will investigate the non-inferiority of a topical IMQ treatment compared to surgical standard treatment in selected patients diagnosed with CIN ...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000269-42 Sponsor Protocol Number: 1-23-456 Start Date*: 2022-06-08
    Sponsor Name:Randers Regional Hospital, Department of Gynecology and Obstetrics
    Full Title: Improving diagnostics in cervical dysplasia
    Medical condition: Abnormal cervical cells
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002096-96 Sponsor Protocol Number: NL57849.068.16 Start Date*: 2016-09-20
    Sponsor Name:Maastricht University Medical Center
    Full Title: TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia, a multicenter, open-label, non-randomized, controlled study (TOPIC-3 study)
    Medical condition: High-grade Cervical Intraepithelial Neoplasia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004023-20 Sponsor Protocol Number: MK-3475-992 Start Date*: 2020-02-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Pa...
    Medical condition: Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) EE (Trial now transitioned) HU (Trial now transitioned) LV (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) IE (Completed) DK (Prematurely Ended) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000879-14 Sponsor Protocol Number: CT/11.01 Start Date*: 2011-06-06
    Sponsor Name:Hellenic Oncology Research Group (H.O.R.G.)
    Full Title: A Phase II Trial of Pazopanib, in Relapsed and Refractory Small Cell Lung Cancer (SCLC).
    Medical condition: Relapsed and Refractory Small Cell Lung Cancer
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003250-34 Sponsor Protocol Number: IVI-ERA-2011 Start Date*: 2011-12-13
    Sponsor Name:IVI Madrid
    Full Title: Endometrial receptivity with different support protocols for the luteal phase in ovarian stimulation cycles in which final oocyte maturation is carried out with GnRH analogues. Analysis by endometr...
    Medical condition: Ovarian Hyperstimulation Syndrome (OHSS)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10033266 Ovarian hyperstimulation syndrome PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005034-42 Sponsor Protocol Number: MK-7684A-008 Start Date*: 2022-01-31
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezoliz...
    Medical condition: Extensive-stage small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) LT (Trial now transitioned) IE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001890-98 Sponsor Protocol Number: HPV001 Start Date*: 2020-05-29
    Sponsor Name:Vaccitech Ltd.
    Full Title: A Phase 1b/2 Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-vectored Multigenotype High Risk Human Papil...
    Medical condition: Persistent hrHPV infection in participants with low grade cervical lesions
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000032-68 Sponsor Protocol Number: 511.77 Start Date*: Information not available in EudraCT
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoacti...
    Medical condition: Primary generalized acquired Hypoactive Sexual Desire Disorder in Premenopausal women
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020933 Hypoactive sexual desire disorder LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) ES (Completed) SE (Completed) HU (Completed) FI (Completed) CZ (Completed) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004076-38 Sponsor Protocol Number: 511.118 Start Date*: 2007-11-30
    Sponsor Name:Boehringer Ingelheim France
    Full Title: A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams dailyin Premenopausal European Women With Hypoactive Sexual Desire Disorder
    Medical condition: Primary generalized acquired Hypoactive Sexual Desire Disorder in Premenopausal women
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020933 Hypoactive sexual desire disorder LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed) NL (Completed) FI (Completed) BE (Completed) ES (Completed) CZ (Completed) SE (Completed) GB (Completed) AT (Prematurely Ended) HU (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004604-31 Sponsor Protocol Number: PCCE201/08 Start Date*: 2008-10-28
    Sponsor Name:Photocure ASA
    Full Title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low-grade cervical intraepithelial neoplasia.
    Medical condition: Low grade cervical intraepithelial neoplasia (CIN)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066238 Cervical low grade squamous intraepithelial lesion LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000417-31 Sponsor Protocol Number: IM101-473 Start Date*: 2014-07-01
    Sponsor Name:University Medical Center Groningen
    Full Title: Randomized, double-blind, placebo-controlled phase III study (ASAP III study) to assess the efficacy and safety of Abatacept treatment in patients with primary Sjögren’s syndrome (ASAP III study = ...
    Medical condition: Primary Sjögren's syndrome (pSS)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10042846 Syndrome Sjogren's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004320-11 Sponsor Protocol Number: MK-3475-867 Start Date*: 2019-05-08
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Me...
    Medical condition: Non-Small Cell Lung Cancer Stage I or IIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 07:01:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA